Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

CTL experiments with mobile technology in teaching and learning
2016-05-23

Description: CTL experiments with mobile technology  Tags: CTL experiments with mobile technology

On the left is Nokukhanya Nkosi, Researcher and Project manager at the Centre for Teaching and Learning presenting Annah Nggoepe her brand new laptop as part of the project which assesses the impact of personal mobile devices on teaching and learning.
Photo: Supplied

Video clip

Same curriculum. Add technology. Wait and see what happens. This research project which is funded by the Department of Higher Education and Training (DHET) seeks to understand the impact of personal mobile devices (PMD) in teaching and learning.

The University of the Free State (UFS), in conjunction with the University of Cape Town, the University of the Witwatersrand, the University of Johannesburg, and Sol Plaatje University, was approached by the DHET to spearhead this national collaborative project. Investigating whether the financial investment of a PMD on either the part of a university or of students adds value to the teaching and learning experience is the overall objective of the project.

Contemporary education
The Centre for Teaching and Learning (CTL) at the UFS have been taking an active part in the project since 2015, focusing specifically on the use of personal mobile devices in teaching and learning by both staff and students.

At the student level, the study will focus specifically on not just the obstacles that first-generation students face in terms of using technology in teaching and learning, but how institutions can support these students through access to these devices.  “In 2015, the CTL conducted the Digital Identity Study of students which highlighted the view that students at the UFS deemed laptops to be the most important PMD in their studies,” said Nokukhanya Nkosi, Researcher and Project manager at the CTL.   

In April 2016, thirty students were presented with laptops funded by the project grant. For the next two years, the CTL will assess whether these laptops enable greater flexibility and effectiveness of teaching and learning, both inside and out of the classroom for these students.  

Rise of the digital classroom
Annah Ngoepe, a second-year Geography and Environmental Management student taking part in this study, commends the shift from using only textbooks in the past to incorporating technology. “The laptop has the latest applications and programmes, which are convenient for me as a student, because they help in my learning. I can also download textbooks, get summaries of the textbooks, and even other people’s views on a particular subject online.”

Tiana van der Merwe, Deputy Director at the CTL, anticipates that, after two years, the Centre would be able to make not only institutional recommendations, but also recommendations to the National Department of Higher Education.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept